Cited by 415Fatty Acid Research and HealthAtherosclerosis and Cardiovascular DiseasesEicosanoids and Hypertension Pharmacology

Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators

Open access
Merched, Aksam J., Ko, Kerry, Gotlinger, Katherine H., Serhan, Charles N., Chan, Lawrence·2008·The FASEB Journal

Abstract

Atherosclerosis is now recognized as an inflammatory disease involving the vascular wall. Recent results indicate that acute inflammation does not simply passively resolve as previously assumed but is actively terminated by a homeostatic process that is governed by specific lipid‐derived mediators initiated by lipoxygenases. Experiments with animals and humans support a proinflammatory role for the 5‐lipoxygenase system. In contrast, results from animal experiments showa range of responses with the 12/15‐lipoxygenase pathways in atherosclerosis. To date, the only two clinical epidemiology human studies both support an antiatherogenic role for 12/15‐lipoxygenase downstream actions. We tested the hypothesis that atherosclerosis results from a failure in the resolution of local inflammation by analyzing apolipoprotein E‐deficient mice with 1 ) global leukocyte 12/15‐lipoxygenase deficiency, 2 ) normal enzyme expression, or 3 ) macrophage‐specific 12/15‐lipoxygenase overexpression. Results from these indicate that 12/15‐lipoxy‐genase expression protects mice against atherosclerosis via its role in the local biosynthesis of lipid mediators, including lipoxin A 4 , resolvin D1, and protectin D1. These mediators exert potent agonist actions on macrophages and vascular endothelial cells that can control the magnitude of the local inflammatory response. Taken together, these findings suggest that a failure of local endogenous resolution mechanisms may underlie the unremitting inflammation that fuels atherosclerosis.—Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N. Chan, L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 22, 3595–3606 (2008)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.08-112201

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many chronic inflammatory diseases, including advanced atherosclerosis, are characterized by an imbalance between pro-resolving and pro-inflammatory mediators such as leukotrienes, leading to defective resolution, tissue injury, and DAMP-mediated inflammation.

    “Many chronic inflammatory diseases, including advanced atherosclerosis, are characterized by an imbalance between pro-resolving and pro-inflammatory mediators, such as leukotrienes, leading to defective resolution of inflammation, tissue injury and damage-associated molecular pattern (DAMP)-mediated inflammation31–33.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 55 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N., & Chan, L.
Affiliations
  • Baylor St. Luke's Medical Center (US)
  • Brigham and Women's Hospital (US)
Venue
The FASEB Journal
Publisher
Wiley
Published
2008-06-17
Volume
22
Issue
10
Pages
3595-3606
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2074102438
Cited by
414
References
55
Citations by year
2026: 6 · 2025: 6 · 2024: 9 · 2023: 20 · 2022: 14 · 2021: 23 · 2020: 22 · 2019: 17 · 2018: 36 · 2017: 27 · 2016: 32 · 2015: 31 · 2014: 30 · 2013: 28 · 2012: 22
FWCI
27.99
Type
journal article
Language
en
Open access
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association (0465093Y, 0730172N)
  • National Institutes of Health (P50 DE016191, HL‐51586)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
atherosclerosis, inflammation resolution, lipid mediators, 12/15-lipoxygenase, 5-lipoxygenase, lipoxin A4, resolvin D1, protectin D1, macrophages, vascular inflammation, ApoE-deficient mice
MeSH terms
Animals, Apolipoproteins E, Arachidonate 12-Lipoxygenase, Arachidonate 15-Lipoxygenase, Docosahexaenoic Acids, Endothelium, Vascular, Humans, Interleukins, Macrophages, Vasculitis, Mice, Knockout, Lipoxins, Atherosclerosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review